Leukemia Research
Volume 28, Issue 10 , Pages 1043-1051 , October 2004

Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia

  • Wolfgang Eisterer

      Affiliations

    • Department of General Internal Medicine, University Hospital, Innsbruck, Austria
    • ,
  • Oliver Bechter

      Affiliations

    • Department of General Internal Medicine, University Hospital, Innsbruck, Austria
    • Bechter O. and Söderberg O. contributed equally to the manuscript.
    • ,
  • Ola Söderberg

      Affiliations

    • Department of Pathology, University of Uppsala, University Hospital, Uppsala, Sweden
    • Bechter O. and Söderberg O. contributed equally to the manuscript.
    • ,
  • Kenneth Nilsson

      Affiliations

    • Department of Pathology, University of Uppsala, University Hospital, Uppsala, Sweden
    • ,
  • Maria Terol

      Affiliations

    • Department of Haematology, Hospital Clinic, Barcelona, Spain
    • ,
  • Richard Greil

      Affiliations

    • Divison of Hematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • ,
  • Josef Thaler

      Affiliations

    • Department of General Internal Medicine, University Hospital, Innsbruck, Austria
    • ,
  • Manfred Herold

      Affiliations

    • Department of General Internal Medicine, University Hospital, Innsbruck, Austria
    • ,
  • Lothar Finke

      Affiliations

    • Delbrück Center for Molecular Medicine, Berlin, Germany
    • ,
  • Ursula Günthert

      Affiliations

    • Basel Institute for Immunology, Basel, Switzerland
    • Present address: Institute for Medical Microbiology, University of Basel, Basel, Switzerland.
    • ,
  • Emilio Montserrat

      Affiliations

    • Department of Haematology, Hospital Clinic, Barcelona, Spain
    • ,
  • Reinhard Stauder

      Affiliations

    • Divison of Hematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43-512-504-23255; fax: +43-512-504-23341.

Received 10 October 2003 ,Accepted 14 January 2004.

References 

  1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 1995;333:1052–1057
  2. Rai KR, Sawitsky A, Cronkite EP. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al.  A new prognostic classification of chronic lymphocytic leukemia derived from multivariate survival analysis. Cancer. 1981;48:198–207
  4. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Sem. Oncol. 1998;25:42–59
  5. Bosch F, Montserrat E. Refining prognostic factors in chronic lymphocytic leukemia. Rev. Clin. Exp. Hematol. 2002;6:335–349
  6. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with the extracellular matrix. Adv. Immunol. 1993;54:271–335
  7. Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, et al.  CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood. 1997;90:2217–2233
  8. Stauder R, Günthert U. CD44 isoforms: impact on lymphocyte activation and differentiation. Immunologist. 1995;3:78–83
  9. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor grwoth in vivo. J. Exp. Med. 1991;174:859–866
  10. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang WM, et al.  A directly spliced exon 10-containing CD44 promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin’s lymphoma. Blood. 1998;91:4282–4291
  11. Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44 immunglobulin fusion protein. J. Exp. Med. 1992;176:623–627
  12. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Krieken JH, Pals S. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/CD18), and ICAM-1 (CD54). Leukemia. 1990;4:595–599
  13. Jalkanen S, Joensuu H, Söderström KO, Klemi P. Lymphocyte homing and clinical behavior in non-Hodgkin’s lymphoma. J. Clin. Invest. 1991;87:1835–1840
  14. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor. Blood. 1995;85:2885–2899
  15. Eisterer W, Hilbe W, Stauder R, Bechter O, Fend F, Thaler J. An aggressive subtype of B-CLL is charcterized by strong CD44 expression and lack of CD11c. Br. J. Haematol. 1996;93:661–669
  16. Zarcone D, De Rossi G, Tenca C, Marroni P, Mauro FR, Cerruti GM, et al.  Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells. Haematologica. 1998;83:1088–1098
  17. Stauder R, VanDriel M, Schwärzler C, Thaler J, Lokhorst HM, Kreuser ED, et al.  Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood. 1996;88:3101–3108
  18. Eisterer W, Bechter O, Hilbe W, Van Driel M, Lokhorst HM, Thaler J, et al.  CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leuk. Res. 2001;25:1051–1057
  19. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. In: Proceedings of the International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989;110:236–8.
  20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al.  A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  21. Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O’Brien S, et al.  National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  22. Söderberg O, Christiansen I, Carlsson M, Nilsson K. CD40 ligation inhibits IL-2 and SAC + IL-2 induced proliferation in chronic lymphocytic leukemia (B-CLL) cells. Scand. J. Immunol. 1997;45:706–714
  23. Banchereau J, De-Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70–72
  24. Rosen A, Uggla C, Szigeti R, Lindqvist C, Zeuthen J. A T-helper cell × Molt4 human hybridoma constitutively producing B-cell stimulatory and inhibitory factors. Lymphokine Res. 1986;5:185–204
  25. Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumour progression?. Cancer Surv. 1995;24:19–42
  26. Pals ST, Drillenburg P, Radaszkiewicz T, Horst EM. Adhesion molecules in the dissemination of non-Hodgkin’s lymphomas. Acta Haematol. 1997;97:73–80
  27. Katoh S, McCarthy JB, Kincade PW. Characterization of soluble CD44 in the circulation of mice: levels are affected by immune activity and tumor growth. J. Immunol. 1994;153:3440–3449
  28. Ristamäki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood. 1994;84:238–243
  29. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–141
  30. De Rossi G, Zarcone D, Mauro F, Cerruti G, Tenca C, Puccetti A, et al.  Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets. Blood. 1993;81:2679–2687
  31. Prystas EM, Parker CJ, Holguin MH, Bohnsack JF. Aberrant glycosilation of l-selectin on the lymphocytes of chronic lymphocytic leukemia. Leukemia. 1993;7:1355–1362
  32. Csanaky G, Matutes E, Vass JA, Morilla R, Catovsky D. Adhesion receptors on peripheral blood leukemic B-cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia. 1997;11:408–415
  33. Domingo A, Gonzalez-Barca E, Castellsague X, Fernandez-Sevilla A, Granena AN, Ferran C. Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: relationship with clinico-prognostic features. Leuk. Res. 1997;21:67–73
  34. Jewell AP, Yong KL. Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukemia. Acta Haematol. 1997;97:67–72
  35. Bazil V, Horejsi V. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J. Immunol. 1992;149:747–753
  36. Ristamäki R, Joensuu H, Grön-Virta K, Salmi M, Jalkanen S. Origin and function of circulating CD44 in non-Hodgkin’s lymphoma. J. Immunol. 1997;158:3000–3008
  37. Niitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk. Res. 2002;26:241–248
  38. Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer. 2001;92:713–719
  39. Beksac M, Arat M, Akan H, Koc H, Ilhan O, Ozcan M. Circulating CD44 and intercellular adhesion molecule-1 levels in low-grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-a-2c treatment. Cancer. 2000;89:1474–1481
  40. Bartolazzi A, Jackson D, Bennet K, Aruffo A, Dickinson R, Shields J, et al.  Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J. Cell Sci. 1995;108:1723–1733
  41. Stauder R, Hamader B, Fasching B, Kemmler B, Thaler J, Huber H. Adhesion to high endothelial venules: a model for dissemination mechanisms in non-Hodgkin’s lymphoma. Blood. 1993;82:262–267
  42. Ristamäki R, Joensuu H, Hagberg H, Kalkner KM, Jalkanen S. Clinical significance of circulating CD44 in non-Hodgkin’s lymphoma. Int. J. Cancer. 1998;79:221–225

PII: S0145-2126(04)00060-8

doi: 10.1016/j.leukres.2004.01.016

Leukemia Research
Volume 28, Issue 10 , Pages 1043-1051 , October 2004

Article Tools

* Image Usage & Resolution